RNA Virus Infections 
Welcome,         Profile    Billing    Logout  

22 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RNA Virus Infections
NCT01821794: Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B

Active, not recruiting
3
26
US
Peginterferon and Tenofovir
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B e Antigen Negative, Chronic Hepatitis B e Antigen Positive
03/13
12/17
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Active, not recruiting
3
428
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
10/15
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

Active, not recruiting
2
60
US
VRX496-Modified Autologous T cells
VIRxSYS Corporation
HIV Infection
11/08
06/23
Rollover, NCT00622232: A Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

Active, not recruiting
2
40
US
VRX496-transduced autologous CD4 T cells
VIRxSYS Corporation
HIV Infections
01/09
06/23
NCT00010348: Study of Total Body Irradiation in Combination With Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation Followed By Cyclosporine and Mycophenolate Mofetil in High Risk-Patients With Human Immunodeficiency Virus-1

Recruiting
2
20
US
Cyclosporine, Mycophenolate mofetil, Total body irradiation and stem cell or bone marrow transplantation
Fred Hutchinson Cancer Research Center
HIV Infections
12/10
12/15
NCT01281423: Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection

Checkmark 8 week
Oct 2011 - Oct 2011: 8 week
Checkmark 12 week
Oct 2011 - Oct 2011: 12 week
Active, not recruiting
2
274
US, Canada, RoW
Placebo, ANA598, Ribavirin, Pegylated Interferon
Hoffmann-La Roche
Hepatitis C
11/12
05/13
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients

Recruiting
2
148
RoW
JKB-122, Placebo
Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd
Chronic Hepatitis C
08/16
 
NCT02031133: Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Active, not recruiting
2
10
US
Miravirsen
Santaris Pharma A/S
Hepatitis C
01/17
01/17
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program

No Longer Available
N/A
US
Atazanavir (BMS-232632)
Bristol-Myers Squibb
HIV Infections
 
07/03
NCT00096811: Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

No Longer Available
N/A
RoW
Entecavir, Baraclude
Bristol-Myers Squibb
Hepatitis B, Chronic Disease
08/08
08/08
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

No Longer Available
N/A
US
Efavirenz, Sustiva, BMS-561525
Bristol-Myers Squibb
HIV Infection
12/10
12/10
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

No Longer Available
N/A
Canada
Efavirenz, Sustiva, BMS-561525
Bristol-Myers Squibb
HIV Infection
12/10
12/10
NCT02011932: Prospective Observational Study of Disease Progression in Chronic Hepatitis C

Active, not recruiting
N/A
133
RoW
Beijing YouAn Hospital
Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis
06/11
07/30
NCT02028819: Compassionate Use of Ibalizumab for the Treatment of HIV Infection

No Longer Available
N/A
US
Dolutegravir Sodium Monohydrate, TIVICAY, Ibalizumab, TMB-355
University of Colorado, Denver
Human Immunodeficiency Virus (HIV)
02/14
02/14
NCT01508286 / 2010-023669-23: Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark HEP3002
More
No Longer Available
N/A
Europe, RoW
Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin
Janssen-Cilag International NV
Hepatitis C
 
 
NCT00975546: HIV-discordant Couple Intrauterine Insemination

No Longer Available
N/A
US
Sperm washing and testing for HIV contamination, Intrauterine Insemination
University of Missouri-Columbia
Infertility, HIV Infections
 
 
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Checkmark VHC 2015
Sep 2015 - Sep 2015: VHC 2015
Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark VHC 2014
More
No Longer Available
N/A
Europe
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Checkmark
Jul 2014 - Jul 2014: 
No Longer Available
N/A
US
Daclatasvir (BMS-790052), Sofosbuvir
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

No Longer Available
N/A
Europe, RoW
Continued Access Arm
ViiV Healthcare, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
 
 
NCT01306071: Observational Study of Persons With Hepatitis B Virus Infection in North America

Recruiting
N/A
200
US
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
 
 
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

No Longer Available
N/A
NA
Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry
ViiV Healthcare, Pfizer
Human Immunodeficiency Virus (HIV)
 
 
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

Recruiting
N/A
2017
Europe
Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen
University of Zurich
HIV Infections
01/25
01/25

Download Options